Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
New insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review.
Eur J Pharmacol
December 2024
Department of Pharmacology, Therapeutics & Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Idi-Araba, P.M.B. 12003, Lagos, Nigeria. Electronic address:
Trimetazidine (TMZ) is a beneficial and well-tolerable anti-anginal drug which has protective action towards ischemia and reperfusion injury. TMZ performs its anti-ischemic effect by modifying cardiac metabolism without shifting the hemodynamic functions, so it represents an outstanding complementary perspective to the general angina treatment. TMZ possesses a positive impact on the inflammatory profile, and also endothelial function furthermore displays various benefits through minimising the number, as well as the intensity of angina strikes and ameliorating the clinical indication and symptoms of myocardium ischemia.
View Article and Find Full Text PDFSubcutaneous electrical nerve stimulation: a feasible and new method for the treatment of patients with refractory angina.
Neuromodulation
February 2012
Faculty of Medicine, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands.
Introduction: Patients suffering from chronic angina pectoris, insufficiently controllable with medication and revascularization, are an increasing medical and psychosocial problem. Although spinal cord stimulation (SCS) is proven to employ, safe, long-term anti-angina, and anti-ischemic effects for these patients, the use of SCS in this group remains limited. The reason for this restricted use is largely unknown.
View Article and Find Full Text PDF[Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
Zhonghua Xin Xue Guan Bing Za Zhi
September 2005
Objective: Trimetazidine has been shown to have anti-ischemic properties by improving exercise tolerance without haemodynamic effects and direct cyto-protective effects on the myocardium. The aim of this study was to assess the effect of trimetazidine on the treatment of patients with ischemic cardiomyopathy, and to assess the anti-angina efficacy and the clinical tolerance of TMZ.
Methods: 60 ischemic cardiomyopathy patients on conventional therapy were enrolled in this open multiple center clinical trial and received TMZ (20 mg 3 times per day) for six months.
[Comparison of continuous and intermittent treatment with glyceryl trinitrate by the transdermal route in stable effort angina].
Ann Cardiol Angeiol (Paris)
March 1994
Service de Cardiologie A, CHU Timone, Marseille.
The anti-angina efficacy of the continuous (C) transdermal application of nitroglycerin may lessen or disappear over the course of time. Pharmacological tolerance, which is probably responsible, might be prevented by intermittent (I) application. However few studies have compared the C and I methods.
View Article and Find Full Text PDF[Combination of anti-angina drugs].
Z Kardiol
January 1990
Division of Cardiovascular Disease, University of Alabama, Birmingham.
Within the last decade it became obvious that the treatment of angina pectoris alone is not sufficient. Modern goals include the optimization of anti-ischemic treatment ("silent myocardial ischemia") without compromising quality of life, as well as the reduction of fatal and non-fatal cardiac events. The failure of nitrates to continuously protect from myocardial ischemia ("nitrate tolerance") requires a modification of the current step-care recommendations for medical treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!